Schistosomiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 40 Published: June 30, 2022 Report Code: GDGMDHC22217IDB

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schistosomiasis – Drugs In Development, 2022, provides an overview of the Schistosomiasis (Infectious Disease) pipeline landscape.

Schistosomiasis is a type of infection caused by parasites that live in fresh water, such as rivers or lakes. Symptoms include a high temperature, headache, cough, a dark red, blotchy, raised skin rash, pain in the abdomen and joint and muscle pain.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schistosomiasis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Schistosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schistosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 1 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.

Schistosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Schistosomiasis (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Schistosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Schistosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Schistosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Schistosomiasis (Infectious Disease)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Schistosomiasis (Infectious Disease).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Schistosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

Helix Biogen Institute

Merck KGaA

Pai Life Sciences Inc

Tongli Biomedical Co Ltd

Villya Pharmaceuticals

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Schistosomiasis – Overview

Schistosomiasis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Schistosomiasis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Schistosomiasis – Companies Involved in Therapeutics Development

Schistosomiasis – Drug Profiles

Schistosomiasis – Dormant Projects

Schistosomiasis – Product Development Milestones

Featured News & Press Releases

Jun 01, 2022: PAI Life Sciences doses first healthy volunteer in schistosomiasis vaccine clinical trial

Nov 25, 2021: Astellas Pharma : Pivotal phase 3 trial for pediatric praziquantel completes with positive results

Nov 16, 2021: Merck announces positive phase III results for Arpraziquantel as part of its schistosomiasis elimination program

Jun 01, 2021: IVI to design adaptive Phase Ib/IIa trial for schistosomiasis vaccine

Jan 18, 2018: George Washington University: Schistosoma vaccine to enter phase Ib clinical trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Schistosomiasis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Schistosomiasis – Pipeline by Helix Biogen Institute, 2022

Schistosomiasis – Pipeline by Merck KGaA, 2022

Schistosomiasis – Pipeline by Pai Life Sciences Inc, 2022

Schistosomiasis – Pipeline by Tongli Biomedical Co Ltd, 2022

Schistosomiasis – Pipeline by Villya Pharmaceuticals, 2022

Schistosomiasis – Dormant Projects, 2022

List of Figures

List of Figures

Number of Products under Development for Schistosomiasis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.